NASDAQ:SY So-Young International Q4 2024 Earnings Report $0.82 -0.03 (-3.41%) As of 03:58 PM Eastern Earnings HistoryForecast So-Young International EPS ResultsActual EPS-$0.07Consensus EPS $0.09Beat/MissMissed by -$0.16One Year Ago EPSN/ASo-Young International Revenue ResultsActual Revenue$50.57 millionExpected Revenue$402.58 millionBeat/MissMissed by -$352.01 millionYoY Revenue GrowthN/ASo-Young International Announcement DetailsQuarterQ4 2024Date3/28/2025TimeBefore Market OpensConference Call DateFriday, March 28, 2025Conference Call Time7:30AM ETUpcoming EarningsSo-Young International's Q1 2025 earnings is scheduled for Tuesday, May 27, 2025, with a conference call scheduled at 7:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesConference Call AudioConference Call TranscriptPress Release (6-K)Annual Report (20-F)Earnings HistoryCompany ProfilePowered by So-Young International Q4 2024 Earnings Call TranscriptProvided by QuartrMarch 28, 2025 ShareLink copied to clipboard.There are 6 speakers on the call. Operator00:00:00thank you for standing by for Sohyoung's Fourth Quarter and Full Year twenty twenty four Earnings Call. As a reminder, today's conference call is being recorded. I would now like to turn the meeting over to your host for today's call, Ms. Mona Kuo. Please go ahead, Mona. Speaker 100:00:26Thank you, operator, and thank you, everyone, for joining Soyang's Fourth Quarter twenty twenty four Earnings Conference Call. Joining me today on the call is Mr. Xin Jin, our Co Founder, Chairman and CEO and Mr. Nick Zhao, CFO. Please note that the discussion today will contain forward looking statements made under the Safe Harbor provisions of The U. Speaker 100:00:47S. Private Securities and the Litigation Reform Act of 1995. Forward looking statements are subject to risks and uncertainties that may cause actual results to differ materially from our current expectations. Potential risks and uncertainties include, but are not limited to those outlined in our public balance with SEC, including our annual report on Form 20 F. Soyeon does not undertake any obligation to update any forward looking statements, except as required under applicable law. Speaker 100:01:23Finally, please note that unless otherwise stated, all fingers mentioned during this conference call are in RMB. At this time, I'd like to turn the call over to Mr. Xin Jin. Hello, everyone, and welcome to today's conference call. In the fourth quarter of twenty twenty four, our total RMB 369,200,000.0. Speaker 100:02:22Net loss attributable to Suyong was $670,600,000 while non GAAP net loss was $53,200,000 The fluctuation in our bottom line was primarily driven by a one time goodwill impairment charge of RMB540 million for our subsidiary, Miracle Laser, as well as our continued investment in the self operated aesthetic center network. During the quarter, we continue to undertake our vertical integration strategy, leveraging our extensive user base, add equity business and upstream supply chain capabilities to drive the rapid expansion of our aesthetic centers. Our Sohyang clinic officially launched with a refreshed bright identity that is focused on providing high quality, cost effective light medical aesthetics and anti agent solutions. They brought refreshing to make medical aesthetics more accessible and empower Chinese consumers to individually pursue aesthetic freedom. They continued high growth of our aesthetic center network demonstrates the viability of its business model and growth potential. Speaker 100:04:38Moving forward, we will continue investing in the business to establish it as a new growth engine for the group. Now let me give you a closer look at our quarterly performance. In Q4, we have opened 19 Zulian clinics across nine core cities, including Beijing, Shanghai, Guangzhou, Shenzhen, Hangzhou, Chengdu, Wuhan, Chongqing and Changsha, all of which are fully operational. Among them, 11 aesthetic centers have already achieved positive monthly operating cash flow in December. Our customer satisfaction remains at an industry leading 4.98 out of five. Speaker 100:06:51Revenue from our aesthetic center business surged to 81,300,000.0 during the quarter, up 79% quarter over quarter and 702% year over year. We recorded over 38,000 verified paid visits. Total number of verified paid aesthetic treatments surpassed 81,500. As of the end of twenty twenty four, total number of active users exceeded 39,500, highlighting the strong appeal of our brand and our deep insight into market demand. We successfully acquired a large number of verified users through our pricing strategies for the double eleven and double twelve sales events and promotional activities following the debut of our aesthetic center on May 20, however, lead to a temporary decline in our per capita revenue, which was an anticipated result of our user acquisition strategy. Speaker 100:09:02Our Beijing Head Aesthetic Center has now matured with repeat customer revenue accounting for the age percentage of total revenue, demonstrating demonstrating the long term appeal of our uniform high quality services. Our Shanghai Center in Super Black Mall is in the and received over 2,000 monthly visits during its fifth month of operation with per square meter sales exceeding 10,000. So strong brand awareness, efficient marketing and robust operational management. We have successfully maintained customer acquisition costs below the industry average. During the quarter, our aesthetic centers officially debuted on the Meituan Dimping, quickly reinforcing its brand recognition. Speaker 100:09:48This channel has generated strong ROI and become a reliable acquisition source for us. Today, none of our aesthetic centers have been integrated into the Soeong app. Instead, customer primarily come from various channels, including the brand influence private domain traffic, other platforms and user referrals. Looking ahead, we plan to deepen our presence in core cities, replicating our proven aesthetic centers across more locations to further expand our network. Our comprehensive medical aesthetic supply chain is yielding results as well. Speaker 100:11:25During the quarter, we served over 1,200 medical institutions with our injectable solutions, reflecting continued growth in our customer base. Demand for injectable remained robust with over 52,000 units shipped during the quarter, up 20% sequentially. This highlights strong market recognition and demand for our products and underscores our product development, quality control and promotional capabilities. We continue to carry out the high quality initiatives for POP, which remains the cornerstone for our traditional business and plays a pivotal role in our overall strategy. As a key profit driver, it will continue to generate stable earnings to support our new business. Speaker 100:12:49During the quarter, GMV for verified medical and aesthetic services reached $356,600,000 up 3% sequentially. Total transaction volume increased 10% year over year, while per capita installed GTV grew by 6% sequentially. As light medical aesthetics come from the medical aesthetic markets, the rise of large scale light medical aesthetic change is inevitable. Unlike traditional institutions that rely on doctor grinding and personalized treatments to command high premiums, this chance will expand rapidly by offering uniform highly cost effective services to achieve economics of scale. First, a sufficient number of locations and market density are essential for building brand awareness and reducing customer acquisition costs. Speaker 100:14:48Second, greater scale involves the development and in house supply chain, lowering procurement cost and expanding profit margins. Lastly, a large network supports a strong digital operations platform, where comprehensive digitalization reduces reliance on human management and ensures a high degree of standardization and consistency across all locations. So, we also advantage in building a mathematical aesthetic chain, lining our strong brand recognition, a fully integrated product supply chain established over the past four years. Our corporate Internet DNA and AI capabilities, which far exceed those of traditional medical aesthetic institutions. What we need now is time to consistently expand and establish more high quality aesthetic centers. Speaker 100:16:23We believe that China will see the emergency of a leading light medical aesthetic chain with over 1,000 locations. Even at that scale, it would account for less than 5% of the total number of medical aesthetic institutions. This is a long term growth opportunity and we have the patience and commitment to emerge as the market leader. Now, I'll hand over to our example Nick, who will walk through the financial results followed by the QA session. Speaker 200:17:01Hello, this is Nick. Please be reminded that our amounts quoted here will be in RMB. Please also refer to our earnings release for detailed information of our comparative financial performances on a year over year basis. Total revenues during the quarter were RMB369.2 million, down 5.5% year over year, primarily due to the decrease in revenue generated by Sohyang Prime. Information reservation services and other revenues were RMB201.5 million, down 27.7% year over year, primarily due to a decrease in revenue generated by Sohyang Prime. Speaker 200:17:43Aesthetic treatment services revenues reached RMB81.3 million, a remarkable 701.6% year over year growth increase, primarily due to the expansion of our aesthetic center business. Sales of medical products and maintenance services were RMB86.2 million, down 15.2% year over year, primarily due to a decrease in order volume for medical equipment. Cost of revenues was RMB153.1 million, up 11.2% year over year, primarily due to the expansion of our aesthetic center business. Within cost of revenues, cost of information, reservation services and others were RMB44.5 million, down 48.2% year over year, primarily due to a decrease in costs associated with Sohyun Prime. Cost of aesthetic treatment services were RMB65.2 million, up 702.3% year over year, primarily due to the expansion of our aesthetic cost center business. Speaker 200:19:00Cost of medical products sold and maintenance services were RMB43.3 million, down 0.5% year over year, primarily due to a decrease in costs associated with the sales of cosmetic injectables. Total operating expenses were RMB800.2 million, up 216.2% year over year. Sales and marketing expenses were RMB134 million, up 6.2 year over year, primarily due to a decrease in payroll costs. G and A expenses were RMB98.4 million, up 13.6% year over year, primarily due to an increase in professional service fees and allowance for credit losses. R and D expenses were RMB42.8 million, down five percent year over year, attributable to improvements in staff efficiency. Speaker 200:20:06Impairment of goodwill was RMB540 million, primarily due to an impairment assessment related to our subsidiary, Americor Laser. Income tax expenses were RMB2.1 million compared with income tax benefits of RMB10.8 million in the same period of 2023. Net loss attributable to Sohyang International Inc. Was RMB607.6 million compared with a net income of RMB17.5 million during the same period last year. Non GAAP net loss attributable to Sohyang International Inc. Speaker 200:20:48Was RMB53.2 million compared with non GAAP net income of RMB35.7 million during the same period of 2023. Basic and diluted loss per ADS attributable to ordinary shareholders were RMB5.92 and RMB5.92 respectively compared with basic and diluted earnings per ADS attributable to ordinary shareholders of RMB0.18 and RMB0.18 respectively during the same period of 2023. For the full year 2024, total revenues were RMB1.47 billion, down 2.1% year over year. Within total revenues, information, reservation services and other revenues were RMB929.5 million, down 19.3% year over year. Aesthetic treatment services revenues were RMB169.3 million, up 1206.1% year over year. Speaker 200:21:59Sales of medical products and maintenance services were RMB368.8 million, up 10.3% year over Operator00:22:09year. Speaker 200:22:11Cost of revenues were RMB567.6 million, up 4.3% year over year, primarily due to the expansion of our aesthetic center business. Total operating expenses were RMB1.552 billion, up 50.1% year over year. Net loss attributable to Sohyang International Inc. Was RMB589.5 million compared with a net income of RMB21.3 million in 2023. Non GAAP net loss attributable to Sohyang International Inc. Speaker 200:22:48Was RMB4.7 million compared with non GAAP net income of RMB58 million in the fiscal year twenty twenty three. Basic and diluted losses per ADS attributable to ordinary shareholders were RMB5.72 and RMB5.72 respectively compared with basic and diluted earnings per ADS attributable to ordinary shareholders of RMB0.21 and RMB0.21, respectively, in fiscal year twenty twenty three. We have maintained a robust cash position and with cash and cash equivalents, restricted cash and term deposits, term deposits and short term investments totaling RMB1.25 billion as of 12/31/2024. Moving to our outlook. For the first quarter of twenty twenty five, we expect total revenues to be between RMB280 million and RMB300 million. Speaker 200:23:55Several of our business initiatives, including both our aesthetic center business and the sales of medical equipment and maintenance services have already yielded impressive results, reinforcing our leading position in the industry. We remain confident that our long term strategy focusing on the vertical integration of the entire aesthetic medical industry and leveraging our core strengths, we enable will enable us to capitalize our new growth opportunities, diversify our revenue streams and drive sustainable growth. Ultimately, this transformation will help us to fulfill our vision of making aesthetic and medical treatment services accessible to a much wider consumer base. With the continuous expansion of our aesthetic center businesses and market conditions stabilizing, we anticipate a steady improvement in our financial performance. This concludes our key remarks. Speaker 200:25:06I will now turn over the call to the operator and open the call for Q and A. Operator00:25:12Thank you. Speaker 200:25:12Operator, we are ready to take questions. Thank you. Operator00:25:15Yes, sir. Thank you. We will now begin the question and answer session. Today's first question comes from Nelson Jones with Citibank. Please go ahead. Operator00:26:01So let me translate the question into English. Bench management for JK, my question. My question is related to the top business and what are the latest developments in merchant support and empowering on your platform during the industry consolidation period? Thank you. Speaker 100:27:40As industry consolidation accelerates, market concentration is inevitable. Large chain institutions are gaining greater market share due to their economics of scale, brand influence and standardized service models. For many specialized medical aesthetic institutions on other platforms, a distributor is key to highlighting their unique technical fiercely competitive market. We continue to optimize our platform business by empowering aesthetic institutions across multiple dimensions, deepen partnerships, reinforcing platform capabilities and improving the user experience. These efforts help institutions navigate market cycles, capitalize on opportunities and achieve sustainable business growth. Speaker 100:28:41For institutions, we continue to strengthen partnerships with top tier and specialized medical aesthetic institutions, fostering closer collaborations through tailor made solutions that empower them to ensure that they maintain their leadership in a competitive market through a segmentation strategy that targets different cities, institutions and service offerings. We optimize our supply structure to better match market demand and supply, improving the overall efficiency of our platform. In terms of operations, we are eager to refine management practices, leveraging user behavior to optimize subsidy plan. Additionally, we continue to enhance the user journey on our app, shorten decision making times and improving retention rates. Furthermore, those doctor, good product initiative, we provide personalized recommendations for medical aesthetic products and services, further enhancing user satisfaction while increasing transaction value. Speaker 100:30:57On the user side, we are continuously strengthening our private domain operations, expanding our user base to provide domain marketing and influencer driven referrals. These efforts enhance our user engagement, unlock customers' LTV and help medical aesthetic institutions reach a broader audience and drive more growth. Driven by these initiatives, we have achieved notable results at this period. Meanwhile, in terms of annual framework agreements, we are making strong progress in both volume and progress. Further validating the effectiveness of our strategy, looking ahead, we will continue to enhance our platform ecosystem, strengthen collaboration with institutions and improve the user experience, fostering the long term sustainable development of the industry. Speaker 100:31:52Thank you. Operator00:31:56Thank you. And our next question today comes from Yibang Li with Haitong Securities. Please go ahead. Speaker 300:32:25Let me translate myself. We are glad to see that Sohyang has opened 19 aesthetic centers as of Q4. So how does the company adapt its strategies and operations for centers at different stages of development? Thank you. Speaker 100:34:02We implement differentiated operational strategy of providing aesthetic centers at various fields of development to ensure they can reach their optimal performance, while continuously building bright influence and enhancing user experience. For aesthetic centers in the Raman 3, which last about three months from our group, the main goal is to build brand awareness and ensure that target customers in a five kilometer radius recognize Zohian's aesthetic centers. We follow SOPs while building the team, providing comprehensive training and strict assessment of doctors, nurses and consultants to ensure service quality at every stage. With twelve years of industry experience, Sohyang has built a private domain community of 1,000,000 users for service engagement with initial customers and significantly lowering market costs. At this point, we focus on delivering outstanding experience to initial customers, minimizing waiting times, improving customer reviews and quickly building extraordinary high quality aesthetic center image through major portal platform like Meituan Dian Pune. Speaker 100:35:20This effort helps strengthen our online reputation and established a solid foundation for long term customer acquisition and retention. As aesthetic centers enter the growth phase, which was from the fourth month to the twelfth month after opening, The focus shifts from brand building to optimizing operational efficiency with an emphasis on service quality and customer retention. We strengthened repeat customer engagement and referral programs to maximize customer lifetime value while gradually balancing operational efficiency to improve financial performance. To this point, most aesthetic centers have established a stable business foundation and are able to generate several consecutive positive cash flow. Speaker 200:37:21When Speaker 100:37:26the aesthetic centers reached the maturity freeze twelve months after the opening, the focus moves to long term customer lifecycle management and service optimization to ensure sustained business growth. At phase three, we implement customer segmentation based on churn frequency, spending levels, past service records and other data. We then develop tailored service codes for the needs of different customer groups. By adopting this segmented operational plan, we can enhance customer loyalty and effectively increase customer lifetime value. Through this real structured strategies, we can ensure that our branded aesthetic centers and different fleets grow progressively, achieve their operational goals and continuously strengthen our brand influence and competitiveness in the market. Speaker 100:38:35Through these well structured strategies, we can ensure that our branded aesthetic centers and different freights grow progressively, achieve their operational goals and continuously strengthen our brand influence and competitiveness in the market. Speaker 300:39:10Let me translate myself. Can aesthetic centers business maintain growth? Thank you. Speaker 100:40:13In my view, Sohuang's aesthetic center network has the capability for sustained growth. From a market wide perspective, they are currently over 20,000 medical aesthetic institutions in China, but the penetration rate of chain clinics remains extremely low with no single brand exceeding 100 locations, representing just a 1% market share. This leaves ample room for expansion. The development of South Korea's medical aesthetic industry serve as a valuable reference as the sector is highly developed with Chainbride's collectively holding a market share exceeding 10%. Software's case demonstrates that as customer awareness and acceptance of medical aesthetics grow. Speaker 100:41:02The Chain model can leverage bright influence, economics of scale and a professional service system to capture a larger market share. Sohuang's chain model presents a highly competitive and differentiated edge in the domestic market. Currently, most traditional institutions follow a restaurant model where operations rely heavily on a filthy doctors, similar to how restaurants rely on seasoned chefs. If these doctors leave, the institution suffers a decline in sales volume, loss of customer trust and damage to its market reputation, making it highly vulnerable to risks. In contrast, Sohuang's aesthetic centers adopt a fast food model, where the cost lies in the establishment and expansion of a uniform service system. Speaker 100:42:48Every aspect of operations from customer reception, medical procedure protocols to product selection standards is thoughtfully designed and standardized. This uniform approach offers multiple advantage. First, it ensures that regardless of which Sohyang aesthetic center a customer visits, they received a consistent, high quality and reliable medical aesthetics experience, significantly enhancing customer satisfaction and brand loyalty. Second, it reduces dependency on individual doctors' proficiencies, prohibiting institutions from being overly affected by staff turnover, thereby improving operational stability and reducing risk. Lastly, this highly standardized model creates a solid foundation for rapid scaling and replication, ensuring long term growth. Speaker 100:44:32Thus, we are confident we can attain a leading position in highly competitive market going forward. Thank you. Operator00:44:43Thank you. And our next question today comes from Jim Teng with CITIC Securities. Please go ahead. Hello, Jim, your line is open. Please proceed. Speaker 400:45:25Okay. So let me just briefly translate for myself. So I am Jason from Peking Securities. Thank you for taking my question. So I have one question about the company's upstream business. Speaker 400:45:36So as we can see, we have acquired like the Mercurator in China and we have multiple partnerships with the upstream companies. So what is our strategy for our upstream business for in general? Thank you. That's my question. Speaker 100:46:49Recently, we successfully completed the full integration of our subsidiary, Miracle Laser, a leading provider of medical aesthetic laser devices in China with strong technical expertise and market advantage. This move is part of Sohuang's upstream business and long term planning. To optimize resource integration and in house business synergies, Miracle Laser has now been incorporated into Sohuya's upstream business unit with a focus on integrating key talent and reinforcing team collaboration. In the medical aesthetic laser segment, Medical Laser will serve as the core foundation, driving product upgrades and innovation to meet market demand and enhance our technology and product portfolio. As the upstream business continues to expand, our product resources will further empower aesthetic centers, driving sustainable growth for the company. Speaker 100:48:21Based on this, our upstream business will focus on several key strategies in the future. First, we will enhance the R and D of high end and best selling products by conducting in-depth market research, analyzing customer behavior and staying ahead of industry trades. We will invest heavily in R and D to build a series of innovative high quality medical aesthetic products tailored to market needs. This will enable us to meet growing need for premium and personalized aesthetic solutions. Additionally, we will ensure a seamless integration between the Miracle Laser and Sohyang teams, leveraging the unique of both sides to establish a highly efficient and collaborative working model. Speaker 100:49:58This will enhance the overall expertise and action oriented capabilities, creating a solid talent foundation to support the Glooskove upstream business. Following the team integration with the combined resources and enhanced capabilities, we will focus on providing Sohyang's aesthetic center with a highly quality and more stable product supply from expanding products variety and ensure delivery to strengthen quality assurance, we aim to empower our aesthetic center network and enhance its service quality and competitiveness. These efforts will drive Sobean's continued growth in the upstream sector. Thank you. Operator00:50:48Thank you. And our next question today comes from Harry Zhao with Deutsche Bank. Please go ahead. Speaker 500:51:10Just let me translate by myself. Thanks for the management for taking my questions. Management just gave the guidance of 2025 revenue guidance and could the management share more insights into the company's financial outlooks in the future? Thank you. Speaker 200:51:30Thank you, Harry, for your question. Looking ahead, we are committed to driving sustainable and high quality growth through the execution of our vertical integration strategy. We have successfully established a full value chain covering both upstream supply chain capabilities to downstream aesthetic treatment services, which creates synergies across our business units. This diversified and balanced model lays a strong foundation for long term financial stability and operational resilience. From a financial perspective, while near term profitability may be impacted by the pace and scale of our new aesthetic center expansion, this business is critical to transitioning towards sustainable high quality growth. Speaker 200:52:25We recognize that different business units are at different stages of development. Some high growth initiatives, such as our aesthetic center business, have just begun to scale and improve operational efficiencies after the success of pilot projects. With healthy cash flow and a disciplined capital allocation approach, we will continue to invest in strategic initiatives that reinforce our market leadership, while maintaining a prudent approach to cost management. Our focus remains on balancing growth with profitability, enhancing financial resilience and ultimately driving long term value for our shareholders. Thank you. Operator00:53:18Thank you. And ladies and gentlemen, this concludes today's question and answer session and today's conference call. We thank you all for attending today's presentation. You may now disconnect your lines and have a wonderful day.Read morePowered by Conference Call Audio Live Call not available Earnings Conference CallSo-Young International Q4 202400:00 / 00:00Speed:1x1.25x1.5x2x Earnings DocumentsPress Release(6-K)Annual report(20-F) So-Young International Earnings HeadlinesSo-Young International Inc. Files Its Annual Report on Form 20-FApril 18, 2025 | gurufocus.comSo-Young International Inc. Files Its Annual Report on Form 20-F | SY Stock NewsApril 18, 2025 | gurufocus.comIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out nearly $5 trillion in wealth from the S&P 500 and $6.4 trillion from the Dow Jones… Not to mention the countless trillions of dollars lost in every market around the world… leaving the major political powers scrambling in fear of Trump’s next move.April 24, 2025 | Porter & Company (Ad)So-Young International Inc. Files Its Annual Report on Form 20-FApril 18, 2025 | prnewswire.comSo-Young controlling shareholder purchases $4.09M in sharesApril 2, 2025 | markets.businessinsider.comSo-Young’s CEO Increases Stake with Major Share PurchaseApril 2, 2025 | tipranks.comSee More So-Young International Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like So-Young International? Sign up for Earnings360's daily newsletter to receive timely earnings updates on So-Young International and other key companies, straight to your email. Email Address About So-Young InternationalSo-Young International (NASDAQ:SY) operates an online platform for consumption healthcare services in the People's Republic of China. The company offers So-Young Mobile App that offers users medical aesthetic knowledge and experience to reach an informed medical aesthetic treatment decision and make reservations for treatment with medical professionals and medical aesthetic institutions; So-Young Beauty which provides similar interfaces and functions as the mobile app, as well as serves as additional access points to the platform; and medical aesthetic community content through its website soyoung.com. It provides content in various media formats on its online platform generated by users, including professional generated, content from in-house editorial team that shares opinions on specific new medical procedures and trends; user generated content comprising Beauty Diaries that provides details about medical institution, doctor, price, and other information on the treatment; professional user generated, contents from the medical aesthetic influencers; and doctor generated, content from doctors to generate knowledge. In addition, the company offers consumption healthcare services, including dermatology, dentistry and orthodontics, physical examinations, gynecology, and postnatal care; reservation services; and software as a service. Further, it engages in research and development, production, sales, and agency of laser and other optoelectronic medical beauty equipment; manufacture and sells light therapy device, surgical laser device and other equipment; internet information and technology advisory; online medical treatment and consultation; management consulting; internet culture; micro finance services, as well as sells cosmetics products. The company was founded in 2013 and is headquartered in Beijing, China.View So-Young International ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Seismic Shift at Intel: Massive Layoffs Precede Crucial EarningsRocket Lab Lands New Contract, Builds Momentum Ahead of EarningsAmazon's Earnings Could Fuel a Rapid Breakout Tesla Earnings Miss, But Musk Refocuses and Bulls ReactQualcomm’s Range Narrows Ahead of Earnings as Bulls Step InWhy It May Be Time to Buy CrowdStrike Stock Heading Into EarningsCan IBM’s Q1 Earnings Spark a Breakout for the Stock? Upcoming Earnings AbbVie (4/25/2025)AON (4/25/2025)Colgate-Palmolive (4/25/2025)HCA Healthcare (4/25/2025)NatWest Group (4/25/2025)Cadence Design Systems (4/28/2025)Welltower (4/28/2025)Waste Management (4/28/2025)AstraZeneca (4/29/2025)Booking (4/29/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
There are 6 speakers on the call. Operator00:00:00thank you for standing by for Sohyoung's Fourth Quarter and Full Year twenty twenty four Earnings Call. As a reminder, today's conference call is being recorded. I would now like to turn the meeting over to your host for today's call, Ms. Mona Kuo. Please go ahead, Mona. Speaker 100:00:26Thank you, operator, and thank you, everyone, for joining Soyang's Fourth Quarter twenty twenty four Earnings Conference Call. Joining me today on the call is Mr. Xin Jin, our Co Founder, Chairman and CEO and Mr. Nick Zhao, CFO. Please note that the discussion today will contain forward looking statements made under the Safe Harbor provisions of The U. Speaker 100:00:47S. Private Securities and the Litigation Reform Act of 1995. Forward looking statements are subject to risks and uncertainties that may cause actual results to differ materially from our current expectations. Potential risks and uncertainties include, but are not limited to those outlined in our public balance with SEC, including our annual report on Form 20 F. Soyeon does not undertake any obligation to update any forward looking statements, except as required under applicable law. Speaker 100:01:23Finally, please note that unless otherwise stated, all fingers mentioned during this conference call are in RMB. At this time, I'd like to turn the call over to Mr. Xin Jin. Hello, everyone, and welcome to today's conference call. In the fourth quarter of twenty twenty four, our total RMB 369,200,000.0. Speaker 100:02:22Net loss attributable to Suyong was $670,600,000 while non GAAP net loss was $53,200,000 The fluctuation in our bottom line was primarily driven by a one time goodwill impairment charge of RMB540 million for our subsidiary, Miracle Laser, as well as our continued investment in the self operated aesthetic center network. During the quarter, we continue to undertake our vertical integration strategy, leveraging our extensive user base, add equity business and upstream supply chain capabilities to drive the rapid expansion of our aesthetic centers. Our Sohyang clinic officially launched with a refreshed bright identity that is focused on providing high quality, cost effective light medical aesthetics and anti agent solutions. They brought refreshing to make medical aesthetics more accessible and empower Chinese consumers to individually pursue aesthetic freedom. They continued high growth of our aesthetic center network demonstrates the viability of its business model and growth potential. Speaker 100:04:38Moving forward, we will continue investing in the business to establish it as a new growth engine for the group. Now let me give you a closer look at our quarterly performance. In Q4, we have opened 19 Zulian clinics across nine core cities, including Beijing, Shanghai, Guangzhou, Shenzhen, Hangzhou, Chengdu, Wuhan, Chongqing and Changsha, all of which are fully operational. Among them, 11 aesthetic centers have already achieved positive monthly operating cash flow in December. Our customer satisfaction remains at an industry leading 4.98 out of five. Speaker 100:06:51Revenue from our aesthetic center business surged to 81,300,000.0 during the quarter, up 79% quarter over quarter and 702% year over year. We recorded over 38,000 verified paid visits. Total number of verified paid aesthetic treatments surpassed 81,500. As of the end of twenty twenty four, total number of active users exceeded 39,500, highlighting the strong appeal of our brand and our deep insight into market demand. We successfully acquired a large number of verified users through our pricing strategies for the double eleven and double twelve sales events and promotional activities following the debut of our aesthetic center on May 20, however, lead to a temporary decline in our per capita revenue, which was an anticipated result of our user acquisition strategy. Speaker 100:09:02Our Beijing Head Aesthetic Center has now matured with repeat customer revenue accounting for the age percentage of total revenue, demonstrating demonstrating the long term appeal of our uniform high quality services. Our Shanghai Center in Super Black Mall is in the and received over 2,000 monthly visits during its fifth month of operation with per square meter sales exceeding 10,000. So strong brand awareness, efficient marketing and robust operational management. We have successfully maintained customer acquisition costs below the industry average. During the quarter, our aesthetic centers officially debuted on the Meituan Dimping, quickly reinforcing its brand recognition. Speaker 100:09:48This channel has generated strong ROI and become a reliable acquisition source for us. Today, none of our aesthetic centers have been integrated into the Soeong app. Instead, customer primarily come from various channels, including the brand influence private domain traffic, other platforms and user referrals. Looking ahead, we plan to deepen our presence in core cities, replicating our proven aesthetic centers across more locations to further expand our network. Our comprehensive medical aesthetic supply chain is yielding results as well. Speaker 100:11:25During the quarter, we served over 1,200 medical institutions with our injectable solutions, reflecting continued growth in our customer base. Demand for injectable remained robust with over 52,000 units shipped during the quarter, up 20% sequentially. This highlights strong market recognition and demand for our products and underscores our product development, quality control and promotional capabilities. We continue to carry out the high quality initiatives for POP, which remains the cornerstone for our traditional business and plays a pivotal role in our overall strategy. As a key profit driver, it will continue to generate stable earnings to support our new business. Speaker 100:12:49During the quarter, GMV for verified medical and aesthetic services reached $356,600,000 up 3% sequentially. Total transaction volume increased 10% year over year, while per capita installed GTV grew by 6% sequentially. As light medical aesthetics come from the medical aesthetic markets, the rise of large scale light medical aesthetic change is inevitable. Unlike traditional institutions that rely on doctor grinding and personalized treatments to command high premiums, this chance will expand rapidly by offering uniform highly cost effective services to achieve economics of scale. First, a sufficient number of locations and market density are essential for building brand awareness and reducing customer acquisition costs. Speaker 100:14:48Second, greater scale involves the development and in house supply chain, lowering procurement cost and expanding profit margins. Lastly, a large network supports a strong digital operations platform, where comprehensive digitalization reduces reliance on human management and ensures a high degree of standardization and consistency across all locations. So, we also advantage in building a mathematical aesthetic chain, lining our strong brand recognition, a fully integrated product supply chain established over the past four years. Our corporate Internet DNA and AI capabilities, which far exceed those of traditional medical aesthetic institutions. What we need now is time to consistently expand and establish more high quality aesthetic centers. Speaker 100:16:23We believe that China will see the emergency of a leading light medical aesthetic chain with over 1,000 locations. Even at that scale, it would account for less than 5% of the total number of medical aesthetic institutions. This is a long term growth opportunity and we have the patience and commitment to emerge as the market leader. Now, I'll hand over to our example Nick, who will walk through the financial results followed by the QA session. Speaker 200:17:01Hello, this is Nick. Please be reminded that our amounts quoted here will be in RMB. Please also refer to our earnings release for detailed information of our comparative financial performances on a year over year basis. Total revenues during the quarter were RMB369.2 million, down 5.5% year over year, primarily due to the decrease in revenue generated by Sohyang Prime. Information reservation services and other revenues were RMB201.5 million, down 27.7% year over year, primarily due to a decrease in revenue generated by Sohyang Prime. Speaker 200:17:43Aesthetic treatment services revenues reached RMB81.3 million, a remarkable 701.6% year over year growth increase, primarily due to the expansion of our aesthetic center business. Sales of medical products and maintenance services were RMB86.2 million, down 15.2% year over year, primarily due to a decrease in order volume for medical equipment. Cost of revenues was RMB153.1 million, up 11.2% year over year, primarily due to the expansion of our aesthetic center business. Within cost of revenues, cost of information, reservation services and others were RMB44.5 million, down 48.2% year over year, primarily due to a decrease in costs associated with Sohyun Prime. Cost of aesthetic treatment services were RMB65.2 million, up 702.3% year over year, primarily due to the expansion of our aesthetic cost center business. Speaker 200:19:00Cost of medical products sold and maintenance services were RMB43.3 million, down 0.5% year over year, primarily due to a decrease in costs associated with the sales of cosmetic injectables. Total operating expenses were RMB800.2 million, up 216.2% year over year. Sales and marketing expenses were RMB134 million, up 6.2 year over year, primarily due to a decrease in payroll costs. G and A expenses were RMB98.4 million, up 13.6% year over year, primarily due to an increase in professional service fees and allowance for credit losses. R and D expenses were RMB42.8 million, down five percent year over year, attributable to improvements in staff efficiency. Speaker 200:20:06Impairment of goodwill was RMB540 million, primarily due to an impairment assessment related to our subsidiary, Americor Laser. Income tax expenses were RMB2.1 million compared with income tax benefits of RMB10.8 million in the same period of 2023. Net loss attributable to Sohyang International Inc. Was RMB607.6 million compared with a net income of RMB17.5 million during the same period last year. Non GAAP net loss attributable to Sohyang International Inc. Speaker 200:20:48Was RMB53.2 million compared with non GAAP net income of RMB35.7 million during the same period of 2023. Basic and diluted loss per ADS attributable to ordinary shareholders were RMB5.92 and RMB5.92 respectively compared with basic and diluted earnings per ADS attributable to ordinary shareholders of RMB0.18 and RMB0.18 respectively during the same period of 2023. For the full year 2024, total revenues were RMB1.47 billion, down 2.1% year over year. Within total revenues, information, reservation services and other revenues were RMB929.5 million, down 19.3% year over year. Aesthetic treatment services revenues were RMB169.3 million, up 1206.1% year over year. Speaker 200:21:59Sales of medical products and maintenance services were RMB368.8 million, up 10.3% year over Operator00:22:09year. Speaker 200:22:11Cost of revenues were RMB567.6 million, up 4.3% year over year, primarily due to the expansion of our aesthetic center business. Total operating expenses were RMB1.552 billion, up 50.1% year over year. Net loss attributable to Sohyang International Inc. Was RMB589.5 million compared with a net income of RMB21.3 million in 2023. Non GAAP net loss attributable to Sohyang International Inc. Speaker 200:22:48Was RMB4.7 million compared with non GAAP net income of RMB58 million in the fiscal year twenty twenty three. Basic and diluted losses per ADS attributable to ordinary shareholders were RMB5.72 and RMB5.72 respectively compared with basic and diluted earnings per ADS attributable to ordinary shareholders of RMB0.21 and RMB0.21, respectively, in fiscal year twenty twenty three. We have maintained a robust cash position and with cash and cash equivalents, restricted cash and term deposits, term deposits and short term investments totaling RMB1.25 billion as of 12/31/2024. Moving to our outlook. For the first quarter of twenty twenty five, we expect total revenues to be between RMB280 million and RMB300 million. Speaker 200:23:55Several of our business initiatives, including both our aesthetic center business and the sales of medical equipment and maintenance services have already yielded impressive results, reinforcing our leading position in the industry. We remain confident that our long term strategy focusing on the vertical integration of the entire aesthetic medical industry and leveraging our core strengths, we enable will enable us to capitalize our new growth opportunities, diversify our revenue streams and drive sustainable growth. Ultimately, this transformation will help us to fulfill our vision of making aesthetic and medical treatment services accessible to a much wider consumer base. With the continuous expansion of our aesthetic center businesses and market conditions stabilizing, we anticipate a steady improvement in our financial performance. This concludes our key remarks. Speaker 200:25:06I will now turn over the call to the operator and open the call for Q and A. Operator00:25:12Thank you. Speaker 200:25:12Operator, we are ready to take questions. Thank you. Operator00:25:15Yes, sir. Thank you. We will now begin the question and answer session. Today's first question comes from Nelson Jones with Citibank. Please go ahead. Operator00:26:01So let me translate the question into English. Bench management for JK, my question. My question is related to the top business and what are the latest developments in merchant support and empowering on your platform during the industry consolidation period? Thank you. Speaker 100:27:40As industry consolidation accelerates, market concentration is inevitable. Large chain institutions are gaining greater market share due to their economics of scale, brand influence and standardized service models. For many specialized medical aesthetic institutions on other platforms, a distributor is key to highlighting their unique technical fiercely competitive market. We continue to optimize our platform business by empowering aesthetic institutions across multiple dimensions, deepen partnerships, reinforcing platform capabilities and improving the user experience. These efforts help institutions navigate market cycles, capitalize on opportunities and achieve sustainable business growth. Speaker 100:28:41For institutions, we continue to strengthen partnerships with top tier and specialized medical aesthetic institutions, fostering closer collaborations through tailor made solutions that empower them to ensure that they maintain their leadership in a competitive market through a segmentation strategy that targets different cities, institutions and service offerings. We optimize our supply structure to better match market demand and supply, improving the overall efficiency of our platform. In terms of operations, we are eager to refine management practices, leveraging user behavior to optimize subsidy plan. Additionally, we continue to enhance the user journey on our app, shorten decision making times and improving retention rates. Furthermore, those doctor, good product initiative, we provide personalized recommendations for medical aesthetic products and services, further enhancing user satisfaction while increasing transaction value. Speaker 100:30:57On the user side, we are continuously strengthening our private domain operations, expanding our user base to provide domain marketing and influencer driven referrals. These efforts enhance our user engagement, unlock customers' LTV and help medical aesthetic institutions reach a broader audience and drive more growth. Driven by these initiatives, we have achieved notable results at this period. Meanwhile, in terms of annual framework agreements, we are making strong progress in both volume and progress. Further validating the effectiveness of our strategy, looking ahead, we will continue to enhance our platform ecosystem, strengthen collaboration with institutions and improve the user experience, fostering the long term sustainable development of the industry. Speaker 100:31:52Thank you. Operator00:31:56Thank you. And our next question today comes from Yibang Li with Haitong Securities. Please go ahead. Speaker 300:32:25Let me translate myself. We are glad to see that Sohyang has opened 19 aesthetic centers as of Q4. So how does the company adapt its strategies and operations for centers at different stages of development? Thank you. Speaker 100:34:02We implement differentiated operational strategy of providing aesthetic centers at various fields of development to ensure they can reach their optimal performance, while continuously building bright influence and enhancing user experience. For aesthetic centers in the Raman 3, which last about three months from our group, the main goal is to build brand awareness and ensure that target customers in a five kilometer radius recognize Zohian's aesthetic centers. We follow SOPs while building the team, providing comprehensive training and strict assessment of doctors, nurses and consultants to ensure service quality at every stage. With twelve years of industry experience, Sohyang has built a private domain community of 1,000,000 users for service engagement with initial customers and significantly lowering market costs. At this point, we focus on delivering outstanding experience to initial customers, minimizing waiting times, improving customer reviews and quickly building extraordinary high quality aesthetic center image through major portal platform like Meituan Dian Pune. Speaker 100:35:20This effort helps strengthen our online reputation and established a solid foundation for long term customer acquisition and retention. As aesthetic centers enter the growth phase, which was from the fourth month to the twelfth month after opening, The focus shifts from brand building to optimizing operational efficiency with an emphasis on service quality and customer retention. We strengthened repeat customer engagement and referral programs to maximize customer lifetime value while gradually balancing operational efficiency to improve financial performance. To this point, most aesthetic centers have established a stable business foundation and are able to generate several consecutive positive cash flow. Speaker 200:37:21When Speaker 100:37:26the aesthetic centers reached the maturity freeze twelve months after the opening, the focus moves to long term customer lifecycle management and service optimization to ensure sustained business growth. At phase three, we implement customer segmentation based on churn frequency, spending levels, past service records and other data. We then develop tailored service codes for the needs of different customer groups. By adopting this segmented operational plan, we can enhance customer loyalty and effectively increase customer lifetime value. Through this real structured strategies, we can ensure that our branded aesthetic centers and different fleets grow progressively, achieve their operational goals and continuously strengthen our brand influence and competitiveness in the market. Speaker 100:38:35Through these well structured strategies, we can ensure that our branded aesthetic centers and different freights grow progressively, achieve their operational goals and continuously strengthen our brand influence and competitiveness in the market. Speaker 300:39:10Let me translate myself. Can aesthetic centers business maintain growth? Thank you. Speaker 100:40:13In my view, Sohuang's aesthetic center network has the capability for sustained growth. From a market wide perspective, they are currently over 20,000 medical aesthetic institutions in China, but the penetration rate of chain clinics remains extremely low with no single brand exceeding 100 locations, representing just a 1% market share. This leaves ample room for expansion. The development of South Korea's medical aesthetic industry serve as a valuable reference as the sector is highly developed with Chainbride's collectively holding a market share exceeding 10%. Software's case demonstrates that as customer awareness and acceptance of medical aesthetics grow. Speaker 100:41:02The Chain model can leverage bright influence, economics of scale and a professional service system to capture a larger market share. Sohuang's chain model presents a highly competitive and differentiated edge in the domestic market. Currently, most traditional institutions follow a restaurant model where operations rely heavily on a filthy doctors, similar to how restaurants rely on seasoned chefs. If these doctors leave, the institution suffers a decline in sales volume, loss of customer trust and damage to its market reputation, making it highly vulnerable to risks. In contrast, Sohuang's aesthetic centers adopt a fast food model, where the cost lies in the establishment and expansion of a uniform service system. Speaker 100:42:48Every aspect of operations from customer reception, medical procedure protocols to product selection standards is thoughtfully designed and standardized. This uniform approach offers multiple advantage. First, it ensures that regardless of which Sohyang aesthetic center a customer visits, they received a consistent, high quality and reliable medical aesthetics experience, significantly enhancing customer satisfaction and brand loyalty. Second, it reduces dependency on individual doctors' proficiencies, prohibiting institutions from being overly affected by staff turnover, thereby improving operational stability and reducing risk. Lastly, this highly standardized model creates a solid foundation for rapid scaling and replication, ensuring long term growth. Speaker 100:44:32Thus, we are confident we can attain a leading position in highly competitive market going forward. Thank you. Operator00:44:43Thank you. And our next question today comes from Jim Teng with CITIC Securities. Please go ahead. Hello, Jim, your line is open. Please proceed. Speaker 400:45:25Okay. So let me just briefly translate for myself. So I am Jason from Peking Securities. Thank you for taking my question. So I have one question about the company's upstream business. Speaker 400:45:36So as we can see, we have acquired like the Mercurator in China and we have multiple partnerships with the upstream companies. So what is our strategy for our upstream business for in general? Thank you. That's my question. Speaker 100:46:49Recently, we successfully completed the full integration of our subsidiary, Miracle Laser, a leading provider of medical aesthetic laser devices in China with strong technical expertise and market advantage. This move is part of Sohuang's upstream business and long term planning. To optimize resource integration and in house business synergies, Miracle Laser has now been incorporated into Sohuya's upstream business unit with a focus on integrating key talent and reinforcing team collaboration. In the medical aesthetic laser segment, Medical Laser will serve as the core foundation, driving product upgrades and innovation to meet market demand and enhance our technology and product portfolio. As the upstream business continues to expand, our product resources will further empower aesthetic centers, driving sustainable growth for the company. Speaker 100:48:21Based on this, our upstream business will focus on several key strategies in the future. First, we will enhance the R and D of high end and best selling products by conducting in-depth market research, analyzing customer behavior and staying ahead of industry trades. We will invest heavily in R and D to build a series of innovative high quality medical aesthetic products tailored to market needs. This will enable us to meet growing need for premium and personalized aesthetic solutions. Additionally, we will ensure a seamless integration between the Miracle Laser and Sohyang teams, leveraging the unique of both sides to establish a highly efficient and collaborative working model. Speaker 100:49:58This will enhance the overall expertise and action oriented capabilities, creating a solid talent foundation to support the Glooskove upstream business. Following the team integration with the combined resources and enhanced capabilities, we will focus on providing Sohyang's aesthetic center with a highly quality and more stable product supply from expanding products variety and ensure delivery to strengthen quality assurance, we aim to empower our aesthetic center network and enhance its service quality and competitiveness. These efforts will drive Sobean's continued growth in the upstream sector. Thank you. Operator00:50:48Thank you. And our next question today comes from Harry Zhao with Deutsche Bank. Please go ahead. Speaker 500:51:10Just let me translate by myself. Thanks for the management for taking my questions. Management just gave the guidance of 2025 revenue guidance and could the management share more insights into the company's financial outlooks in the future? Thank you. Speaker 200:51:30Thank you, Harry, for your question. Looking ahead, we are committed to driving sustainable and high quality growth through the execution of our vertical integration strategy. We have successfully established a full value chain covering both upstream supply chain capabilities to downstream aesthetic treatment services, which creates synergies across our business units. This diversified and balanced model lays a strong foundation for long term financial stability and operational resilience. From a financial perspective, while near term profitability may be impacted by the pace and scale of our new aesthetic center expansion, this business is critical to transitioning towards sustainable high quality growth. Speaker 200:52:25We recognize that different business units are at different stages of development. Some high growth initiatives, such as our aesthetic center business, have just begun to scale and improve operational efficiencies after the success of pilot projects. With healthy cash flow and a disciplined capital allocation approach, we will continue to invest in strategic initiatives that reinforce our market leadership, while maintaining a prudent approach to cost management. Our focus remains on balancing growth with profitability, enhancing financial resilience and ultimately driving long term value for our shareholders. Thank you. Operator00:53:18Thank you. And ladies and gentlemen, this concludes today's question and answer session and today's conference call. We thank you all for attending today's presentation. You may now disconnect your lines and have a wonderful day.Read morePowered by